Table 2.

Gadolinium-based contrast agents grouped according to the associated risk of nephrogenic systemic fibrosis (based on ESUR CMSC guideline ver. 10.0)

Gadolinium-based contrast agents – risk classification (based on esur cmsc guideline version 10.0)
Highest risk	Gadodiamide (Omniscan®) Ligand: Nonionic linear chelate (DTPA-BMA) Gadopentetate dimeglumine (Magnevist®) Ligand: Ionic linear chelate (DTPA) Gadoversetamide (Optimark®) Ligand: Nonionic linear chelate (DTPA-BMEA)
Intermediate risk	Gadobenate dimeglumine (Multihance®) Ligand: Ionic linear chelate (BOPTA) Gadoxetate disodium (Primovist®, Eovist®) Ligand: Ionic linear chelate (EOB-DTPA)
Lowest risk	Gadobutrol (Gadovist®, Gadavist®) Ligand: Nonionic Cyclic Chelate (BT-DO3A) Gadoterate meglumine (Dotarem®, Magnescope® plus generic products) Ligand: Ionic Cyclic Chelate (DOTA) Gadoteridol (Prohance®) Ligand: Non-ionic cyclic chelate (HP-DO3A)